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Abstract 
Multicriteria Decision Analysis (MCDA) is, rightly, receiving increasing attention in Health 
Technology Assessment.  However, a distinguishing feature of the health domain is that technologies 
must actually improve health, and good performance on other criteria cannot compensate for failure to 
do so.  We argue for two reasonable tests for MCDA models: the treacle test (can a winning 
intervention be incompletely ineffective?) and the smallpox test (can a winning intervention be for a 
disease which noone suffers from?).  We explore why models might fail such tests (as the models of 
some existing published studies would do) and offer some suggestions as to how practice should be 
improved. 
Introduction 
As Health Technology Assessment (HTA) becomes more widely used in jurisdictions around the 
world, and for a wider range of medical technologies and services, several voices have called for the 
discipline to give greater recognition to the range of values which decision makers bring to bear in 
making decisions, alongside maximising health.  In particular, there has been increased interest in 
Multicriteria Decision Analysis (MCDA) as a framework for making decisions, as a complement or 
even an alternative to the standard techniques of economic evaluation.  This growth in interest can be 
seen both in the growth of publications on this topic in leading HTA journals over the last few years 
(see Figure 1 for a count of articles mentioning MCDA in the title or abstract according to Web of 
Science), as well as the recent publication of the ISPOR task force on MCDA1,2 and recent reviews 
and advocacy 3,4. 
 Figure 1 
The attraction of MCDA is that it offers a way to include many of the values which decision makers 
care about beyond immediate population health gains (measured for example through QALYs) and 
money.  It is incontrovertible that such values exist.  For example: (i) enormous amounts of ink have 
been spilled on the existence and implications of distributional preferences for health, according to 
which different sorts of people are given priority, such as the young .   (ii) The DCP3 project which 
aims to produce guides to cost effectiveness of healthcare in low- and middle-income countries uses 
DQ³([WHQGHG&RVW(IIHFWLYHQHVV´DSSURDFKLQZKLFKthe insurance benefits of coverage are calculated 
6
.  This recognises the important financial protection role of the public healthcare system in many 
poorer countries, where many people are currently exposed to substantial financial risk in the event 
that they fall ill.  (iii) Many stakeholders have argued that current HTA decision rules are failing to 
fully account for the different sources of value of new antibiotics, which should be rewarded for their 
innovativeness relative to the current available armamentarium, as drugs with novel mechanisms of 
action can be expected to hold their own against resistance 7.   
Such concerns have filtered through to discussions about how HTA agencies should make decisions 
or decision recommendations.  The Scottish Medicines Consortium, for example, considers whether 
FHUWDLQ³GHFLVLRQPRGLILHUV´apply in making its decisions in addition to cost-effectiveness 8; the HTA 
agency for England, NICE, recently considered (and ultimately rejected) wide-ranging changes to its 
processes in order to formally account for non-cost-effectiveness related considerations in its 
decisions 9; and an equity concept, that of ³SURSRUWLRQDOVKRUWIDOO´IHDWXUHVSURPLQHQWO\LQWKH'XWFK
decision framework 10. 
The core idea of MCDA is to treat these additional values in a systematic manner.  Thus, roughly 
following the ISPOR taskforce, the main stages of the MCDA process are: defining the decision 
problem; identifying and structuring the criteria;  measuring performance of alternatives on the 
different scoring; scoring the alternatives (or perhaps more accurately, scoring the performance levels 
of the alternatives); weighting criteria; calculating overall scores; performing sensitivity analysis; and 
reporting analysis to decision makers. 
Of course, the existence of such values does not necessarily imply that MCDA (understood as a 
formal body of techniques) should necessarily have a role in the HTA process.  It may be perfectly 
satisfactory to take these values into account informally, as part of the deliberative process which 
surrounds a formal analysis based on traditional CEA.  While my view is that MCDA can add real 
value and insight, I believe that the standard CEA paradigm contains an important insight which is 
relevant for the structuring of MCDA models for HTA.  This insight is that health improvement is not 
one among a number of criteria in the assessment of a medical technology: it is at the absolute core of 
our reasons for developing and providing such technologies.   
Two tests 
In this commentary, I outline two tests which I believe that any MCDA model should pass in order to 
qualify as fit for purpose for its use in HTA processes.  These tests are as follows: 
x the treacle test: it should not be possible for a completely clinically ineffective intervention (such 
as Venice treacle, a popular 17th century treatment for bubonic plague11) to get a higher overall 
score than an intervention which does patients some positive good, eg because the ineffective 
intervention is intended for severely (perhaps terminally) ill patients, children, or disadvantaged 
population groups. 
x the smallpox test: it should not be possible for a treatment for a disease with zero global 
prevalence to get a higher overall score than a treatment for a disease which actually affects some 
people in the population (for example because the treatment is cost effective, easy to administer, 
or there is a convincing evidence base). 
I do not believe these tests are unreasonably demanding.  Yet many published MCDA models in the 
HTA literature would potentially fail them.  For example, many MCDA models have a criterion 
³GLVHDVH VHYHULW\´ ZKLFK LV DVVLJQHG D VFRUH to be summed up with other criterion scores 12 13  14.   
Smallpox, although declared by the UN to be eradicated in 1980, is a serious disease, with a high case 
fatality rate, and so on this principle, smallpox vaccination could get several points on this criterion: 
say the score which smallpox gets on the disease severity criterion is s and the weight associated with 
this criterion is w.  Now consider another intervention targeted at a troublesome but non-life 
threatening disease which has not yet been eradicated, which receives a score on the severity criterion 
of t<s.  Now as long as the aggregate weighted scores on the other criteria total less than w(s-t), 
smallpox vaccination will get a higher score than our second intervention, which, although perhaps 
unattractive in many ways, is nevertheless effective against a disease which some people actually 
have.   Similarly, Venice treacle, though now no longer regarded as an effective treatment for bubonic 
plague, would get points simply for being targeted at severely ill patients, and these points could 
balance out its therapeutic ineffectiveness.   
This is not a hypothetical argument.  For example, in the model of Wilson et al 15, the four 
interventions W, X, Y and Z have overall scores of 6.21, 5.45, 7.87 and 3.05, respectively, based on 
ZHLJKWHG VFRUHV IURP VHYHQ FULWHULD LQFOXGLQJ FULWHULD ³QHHG´ RSHUDWLRQDOLVHG WKURXJK TXHVWLRQV
inclXGLQJ³:KDWLVWKHSUHYDOHQFHLQFLGHQFHRIWKHGLVHDVHRUFRQGLWLRQWKLVSURSRVDOLVLQWHQGHGWR
WUHDW"´DQG³HIIHFWLYHQHVV´ RSHUDWLRQDOLVHG WKURXJKTXHVWLRQV LQFOXGLQJ³,V WKHSURSRVDOSURYHQ WR
ZRUN"´7KXVZLWKWKHRULJLQDOQXPEHUVRIWKHPRGHORption Y seems the most attractive alternative.  
,IWKHVFRUHIRU³QHHG´IRU<LVVHWWR]HURNHHSLQJHYHU\WKLQJHOVHFRQVWDQWWKHQLWVRYHUDOOYDOXHLV
reduced to 6.09, which is lower than the overall score of W, but still higher than the overall score of X 
DQG=  ,IDGGLWLRQDOWRVHWWLQJWKHVFRUHIRU³QHHG´WR]HURZHDOVRVHWWKH³HIIHFWLYHQHVV´VFRUHWR
zero, option Y now has an overall score of 5.04, which is still higher than that of option Z.  Thus the 
model may prioritise an intervention which is a completely ineffective treatment for a disease which 
noone has over a treatment which stands to yield some clinical benefit to patients. 
One objection to this line of reasoning is that in practical evaluation settings, Venice treacle and 
smallpox vaccination are not interventions which would be realistically considered.  This is to 
misunderstand the key point here.  A decision rule which produces absurd results in cases where the 
answer is obvious should not be trusted as guide to wise decision making in situations which are 
harder to call. 
A short detour into theory 
0&'$ DSSOLFDWLRQV XVH ZKDW , ZLOO FDOO DQ ³HYDOXDWLRQ PRGHO´  $Q HYDOXDWLRQ PRGHO LV D
mathematical formula which describes how the criterion-level evaluations translate into an overall 
score for the objects of assessment.  The evaluation model may be written down as a mathematical 
function such as  σ ୨୨ሺήሻ୨  where j indices criteria and w is a vector of weights and vj(·) is a set of 
criterion-level scoring functions.  Alternatively (but equivalently) the evaluation model may be 
described as set of procedurHV³VFRUHRSWLRQVRQWKHGLIIHUHQWFULWHULDZHLJKWWKHVFRUHVDQGDGGWKHP
XS´ In principle there are an infinite number of different evaluation models (as many as there are 
mathematical functions).  The main purpose of this note is to critique the use of the additive 
evaluation model σ ୨୨ሺήሻ୨  in a HTA setting where the set of criteria includes criteria such as 
population need and clinical effectiveness, and also concepts such as equity or severity. 
The  additive evaluation model  is a widely used and familiar evaluation model in many domains of 
life.  To understand why the additive model produces results which seem odd in this setting we need 
to delve back in the underpinning theory of MCDA.  As recognised by the ISPOR task force in their 
second paper (p 128), the additive model embeds an important preferential independence assumption 
± namely how much I care about performance on one criterion does not depend on performance on 
the other criteria.  This is surely not true for health technologies: a health technology which does not 
actually improve the health of some actual people is worthless, irrespective of whether it is intended 
for people with rare diseases, at the end of life, whether it is deployed in a particularly accessible way, 
or whether the quality of the evidence for its (non-) effectiveness is particularly strong. 
In a properly conducted MCDA which uses a theoretically grounded weighting technique, such as 
swing weighting (as recommended by the ISPOR task force), in a genuinely deliberative way, failures 
of this independence assumption should become evident.  Swing weighting, to recall, involves asking 
the question: ³How much do you care about a worst-to-best improvement on a given criterion, all 
other things being equal?´  If I was asked such a question about a criterion like ³GLVHDVHVHYHULW\´
my response ZRXOGEH³I cannot tell you how important a change in the disease severity of the target 
patient group would be to my evaluation of the treatment: it depends on how effective the treatment is 
DQGKRZPDQ\SHRSOHFDQEHQHILW´.  I believe that many thoughtful individuals would respond in a 
similar way if they are given time to properly understand the question.  Of course, it is always 
possible to get people to give numbers by asking vague questions 16, and/ or by simply bulldozing 
WKURXJKUHVSRQGHQWV¶GRXEWVDERXWZKDWWKH\DUHEHLQJDVNHG%XWthis misses the point of decision 
analysis, which is to aid reflection and deepen understanding of a decision problem, not to produce 
numbers. 
Possible remedies 
Standard MCDA texts 17 18 suggests that there are two approaches to situations where there is a failure 
of additive independence: restructure the model or choose a different functional form for the 
evaluation model.  
x Restructuring the model.  If I have an evaluation model for selection of a place to live and I have 
two criteria which capture closeness to park and closeness to swimming pool, I might 
subsequently discover a failure of preferential independence (I like to either go for a run or a 
swim in the morning: if my house is close to the park, I no longer care about closeness to the 
swimming pool).  In this case, an appropriate action would be to restructure the model, replacing 
these two criteria with a single criterion: closeness to exercise facilities.  In the HTA context, 
however, an example of such a restructuring might be replacing an effectiveness and a disease 
severity criterion with a criterion which is concerned with minimising the population shortfall 
relative to some reference level of health (for example one might aspire to raise the life 
expectancy of those suffering from some disease to within 90% of the level of the general 
population). 
x Choosing a different functional form for the evaluation model.  While there are a range of 
different functional forms available, beyond the additive model, one simple and practical 
functional form is a multiplicative one, whereby scores on different criteria are multiplied through 
to come up with an overall index of value  (e.g. the ISafE model used in the selection of the Thai 
essential medicines list 19).  This seems an intuitive functional form in the health technology 
assessment context.  The arithmetic of the multiplicative model is no harder than the arithmetic of 
the additive model (which, after all, also involves multiplication) and will be familiar to anyone 
with at least primary school education.  (Indeed, the concept of the QALY as a measure of time-
integrated health related well-being requires high school mathematical background but this is now 
well-understood and accepted.)  Indeed, the practice of applying less stringent cost effectiveness 
thresholds for particular classes of technology can be considered as implying a multiplicative 
value model.  For example, applying a cost-effectiveness threshold of £50,000 rather than 
£30,000 for life-extending treatments for patients at the eQGRIOLIHDPRXQWVWR³XSZHLJKWLQJ´WKH
QALYs of patients at end of life by a multiplier of 5/3.  
Both these responses preserve the important intuition that there are things which do and should matter 
in decision making alongside health and money, but recognises that these additional considerations 
complement rather than substitute for health gain, which must be the central aim of any health 
technology. 
Conclusion 
The philosophy of this commentary is that decision rules should reflect and embody sound decision 
making principles.  A sure sign that a decision rule is faulty is if one applies it to a situation where the 
answer is obvious and it produces the wrong result.  Analysts who recommend such rules weaken 
their credibility ± and the credibility of the entire discipline ± in the eyes of decision makers. 
Rather than brainstorming criteria and using scoring and weighting to construct an overall value score, 
MCDA practice in HTA should try to ensure that value is modelled in a way which makes sense.  My 
key point is that clinical effectiveness and population need are not criteria on an equal footing with 
others: they are the foundational, in the sense that without them, there can be no value.   
As a way to test out whether a particular modelling approach makes sense, two tests are offered: the 
treacle test (can a winning intervention be incompletely ineffective?) and the smallpox test (can a 
winning intervention be for a disease which noone suffers from?).  An evaluation model which fails 
these natural and reasonable tests should be treated with great suspicion. 
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